收费全文 | 4390篇 |
免费 | 184篇 |
国内免费 | 38篇 |
耳鼻咽喉 | 89篇 |
儿科学 | 65篇 |
妇产科学 | 51篇 |
基础医学 | 526篇 |
口腔科学 | 73篇 |
临床医学 | 290篇 |
内科学 | 1616篇 |
皮肤病学 | 32篇 |
神经病学 | 311篇 |
特种医学 | 84篇 |
外科学 | 711篇 |
综合类 | 10篇 |
预防医学 | 113篇 |
眼科学 | 60篇 |
药学 | 276篇 |
中国医学 | 4篇 |
肿瘤学 | 301篇 |
2023年 | 31篇 |
2022年 | 64篇 |
2021年 | 136篇 |
2020年 | 79篇 |
2019年 | 98篇 |
2018年 | 126篇 |
2017年 | 83篇 |
2016年 | 93篇 |
2015年 | 95篇 |
2014年 | 137篇 |
2013年 | 159篇 |
2012年 | 300篇 |
2011年 | 271篇 |
2010年 | 174篇 |
2009年 | 169篇 |
2008年 | 250篇 |
2007年 | 281篇 |
2006年 | 278篇 |
2005年 | 283篇 |
2004年 | 250篇 |
2003年 | 238篇 |
2002年 | 209篇 |
2001年 | 46篇 |
2000年 | 52篇 |
1999年 | 45篇 |
1998年 | 40篇 |
1997年 | 23篇 |
1996年 | 30篇 |
1995年 | 15篇 |
1994年 | 28篇 |
1993年 | 17篇 |
1992年 | 41篇 |
1991年 | 23篇 |
1990年 | 30篇 |
1989年 | 30篇 |
1988年 | 30篇 |
1987年 | 23篇 |
1986年 | 29篇 |
1985年 | 39篇 |
1984年 | 29篇 |
1983年 | 27篇 |
1982年 | 16篇 |
1981年 | 14篇 |
1979年 | 27篇 |
1978年 | 20篇 |
1977年 | 22篇 |
1976年 | 21篇 |
1975年 | 15篇 |
1974年 | 18篇 |
1973年 | 10篇 |
Summary
Platelet count represents a useful tool in clinical practice to discriminate individuals at higher risk of bleeding. Less obvious is the role of platelet count variability within the normal range of distribution in shaping the individual's disease risk profile. Epidemiological studies have shown that platelet count in the adult general population is associated with a number of health outcomes related to hemostasis and thrombosis. However, recent studies are suggesting a possible role of this platelet index also as an independent risk factor. In this review of adult population studies, we will first focus on known genetic and non‐genetic determinants of platelet number variability. Next, we will evaluate platelet count as a marker and/or a predictor of disease risk and its interaction with other risk factors. We will then discuss the role of platelet count variability within the normal distribution range as a contribution to disease and mortality risk. The possibility of considering platelet count as a simple, inexpensive indicator of increased risk of disease and death in general populations could open new opportunities to investigate novel platelet pathophysiological roles as well as therapeutic opportunities. Future studies should also consider platelet count, not only platelet function, as a modulator of disease and mortality risk.Objective
To investigate whether oldest-old age (≥85y) is an independent predictor of exclusion from stroke rehabilitation.Design
Retrospective cohort study.Setting
Stroke unit (SU) of a tertiary hospital.Participants
Elderly patients (N=1055; aged 65–74y, n=230; aged 75–84y, n=432; aged ≥85y, n=393) who, between 2009 and 2012, were admitted to the SU with acute stroke and evaluated by a multiprofessional team for access to rehabilitation. The study excluded patients for whom rehabilitation was unnecessary or inappropriate.Interventions
Not applicable.Main Outcome Measures
Access to an early mobilization (EM) protocol during SU stay and subsequent access to postacute rehabilitation after SU discharge. Analyses were adjusted for prestroke and stroke-related characteristics.Results
32.2% of patients were excluded from EM. Multivariable-adjusted odds ratios (ORs) of EM exclusion were 1.30 (95% confidence interval [CI], .76–2.21) for ages 75 to 84 years and 2.07 (95% CI, 1.19–3.59) for ages ≥85 years compared with ages 65 to 74 years. Of 656 patients admitted to EM and who, at SU discharge, had not yet fully recovered their prestroke functional status, 18.4% were excluded from postacute rehabilitation. For patients able to walk unassisted at SU discharge, the probability of exclusion did not change across age groups. For patients unable to walk unassisted at SU discharge, ORs of exclusion from postacute rehabilitation were 3.74 (95% CI, 1.26–11.13) for ages 75 to 84 years and 9.15 (95% CI, 3.05–27.46) for ages ≥85 years compared with ages 65 to 74 years.Conclusions
Oldest-old age is an independent predictor of exclusion from stroke rehabilitation. 相似文献Patients with patent foramen ovale (PFO) and cryptogenic ischemic stroke (CS) are at risk for stroke recurrence. The optimal antithrombotic strategy in patients who undergo medical management is still debated.
MethodsWe systematically searched the literature for studies that reported on cerebrovascular event recurrences and/or death in patients with PFO treated with oral anticoagulation (OAC) or antiplatelet therapy (APT) for secondary prevention of CS. The efficacy endpoints were stroke recurrence and the composite of stroke, transient ischemic attack or all-cause death. Major bleedings represented the safety endpoint.
ResultsA total of 16 studies with 3953 patients (OAC?=?1527, APT?=?2426) were included. Weighted mean follow-up was 2.9 years. OAC was associated with a significant reduction in the risk of stroke compared with APT (RR 0.65; 95% CI 0.44–0.95; ARR 2%, NNT 49), while no difference was found regarding the composite outcome (RR 0.78; 95% CI 0.57–1.07) and the safety outcome (RR 1.57; 95% CI 0.85–2.90; p?=?0.15).
ConclusionsOAC was more effective than APT in reducing the risk of stroke recurrence in patients with PFO and CS, without a significant increase in the risk of major bleedings. Our findings support the need for further randomized data focused on the comparison of antithrombotic strategies in this setting.
相似文献